Wilkinson L, Gathani T (2022) Understanding breast cancer as a global health concern. Br J Radiol. 95(1130):20211033

Article  PubMed  Google Scholar 

Fares MY, Salhab HA, Khachfe HH, Khachfe HM (2019) Breast cancer epidemiology among Lebanese women: an 11-Year analysis. Medicina (Mex). 55(8):463

Article  Google Scholar 

Jalkh N, Chouery E, Haidar Z, Khater C, Atallah D, Ali H et al (2017) Next-generation sequencing in familial breast cancer patients from Lebanon. BMC Med Genomics. 10(1):8

Article  PubMed  PubMed Central  Google Scholar 

Devi S (2020) Economic crisis hits Lebanese health care. The Lancet. 395(10224):548

Article  Google Scholar 

Baff S. The Fluctuation of Lebanese Lira Against the US Dollar In the Parallel Market.

Eid D, Jabbour J, Moujaes E, Kourie HR, Safieddine M, Kattan J (2024) Impact of the economic crisis and drug shortage on Lebanese cancer patients’ care. World J Clin Oncol. 15(5):644–52

Article  PubMed  PubMed Central  Google Scholar 

Fleifel M, Abi Farraj K (2022) The Lebanese healthcare crisis: an infinite calamity. Cureus. https://doi.org/10.7759/cureus.25367

Article  PubMed  PubMed Central  Google Scholar 

Kattan C, Kattan J (2023) Accommodation with anticancer drug shortage: A Lebanese harmful solution. Front Oncol. 18(12):1055113

Article  Google Scholar 

Jaber Chehayeb R, Kala S, Abou Ghannam H, Hasan G, Salloum J (2023) The evolving Lebanese drug crisis: Trends in drug availability and affordability for common outpatient diseases from 2019 to 2023. PLOS Global Public Health. 3(11):e0002538

Article  PubMed  PubMed Central  Google Scholar 

Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 375(20):1925–36

Article  CAS  PubMed  Google Scholar 

Finn RS, Aleshin A, Slamon DJ (2016) Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 18(1):17

Article  PubMed  PubMed Central  Google Scholar 

Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A et al (2015) FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. 21(21):4760–6

Article  CAS  PubMed  Google Scholar 

Gharib KE, Macaron W, Kattan J, Salloum MA, Farhat F, Smith M et al (2022) Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors. Curr Probl Cancer. 46(3):100859

Article  PubMed  Google Scholar 

Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I et al (2016) Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res. 18(1):67

Article  PubMed  PubMed Central  Google Scholar 

Finn RS, Boer K, Bondarenko I, Patel R, Pinter T, Schmidt M et al (2020) Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Res Treat. 183(2):419–28

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mayer EL, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein HJ, Zdenkowski N et al (2022) Treatment exposure and discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With adjuvant endocrine therapy for hormone receptor–positive/human epidermal growth factor receptor 2–negative early breast cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). J Clin Oncol. 40(5):449–58

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buijs SM, Ali MIM, de Hoop EO, Braal CL, Wortelboer N, Van Ommen-Nijhof A et al (2024) 363P Palbociclib exposure in relation to response and toxicity in patients with advanced breast cancer. Ann Oncol. 35:S369

Article  Google Scholar 

Zheng J, Yu Y, Durairaj C, Diéras V, Finn RS, Wang DD (2021) Impact of dose reduction on efficacy: implications of exposure-response analysis of palbociclib. Target Oncol. 16(1):69–76

Article  PubMed  Google Scholar